Clinical Trials
6
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:2
Not Applicable:4
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Not Applicable
4 (66.7%)Phase 1
2 (33.3%)Echography Study_Anthropometric Measurements
Not Applicable
Recruiting
- Conditions
- Healthy Subjects
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-07-22
- Lead Sponsor
- Crossject
- Target Recruit Count
- 90
- Registration Number
- NCT06279689
- Locations
- 🇺🇸
Clinical Trials of Texas, LLC dba Flourish Research, San Antonio, Texas, United States
Evaluation by Magnetic Resonance Imaging of Intramuscular Injections Performance in Thigh With 2 Configurations of the Needle-free Injector ZENEO®.
Not Applicable
Completed
- Conditions
- Needle-free Injector
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-04-01
- Lead Sponsor
- Crossject
- Target Recruit Count
- 63
- Registration Number
- NCT05967013
- Locations
- 🇫🇷
CHU DIJON Bourgogne - Hôpital François Mitterrand, Dijon, France
Bioavailability Study of Midazolam Administered as a Solution by Conventional Syringe or ZENEO®
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Combination Product: ZENEO® Midazolam (10 mg/0.625 mL) on bare skin in thighCombination Product: ZENEO® Midazolam (10 mg / 0.625 mL) through clothing in thighCombination Product: ZENEO® Midazolam (10 mg / 0.625 mL) on bare skin in ventrogluteal area
- First Posted Date
- 2021-08-30
- Last Posted Date
- 2022-07-22
- Lead Sponsor
- Crossject
- Target Recruit Count
- 40
- Registration Number
- NCT05026567
- Locations
- 🇿🇦
FARMOVS Pty Ltd, Bloemfontein, South Africa
Performance Evaluation by Magnetic Resonance Imaging (MRI) of Intramuscular Thigh Injections With 3 Configurations of Needle-free Injector (ZENEO®)
Not Applicable
- Conditions
- No Condition
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- Crossject
- Target Recruit Count
- 86
- Registration Number
- NCT03225638
A Bioavailability Study of Methotrexate 25 mg Administered by Needle Injection and a Pre Filled Needle-free Device in Healthy Volunteers.
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Other: Zeneo® - Methotrexate
- First Posted Date
- 2017-04-06
- Last Posted Date
- 2021-02-16
- Lead Sponsor
- Crossject
- Target Recruit Count
- 58
- Registration Number
- NCT03103334
- Prev
- 1
- 2
- Next
News
CROSSJECT Reports Positive 6-Month Stability Data for ZEPIZURE Epilepsy Auto-Injector
CROSSJECT has achieved satisfactory 6-month room temperature stability results for its ZEPIZURE registration batch, a critical milestone in the regulatory submission process for its needle-free epilepsy treatment.